ArticleCephalalgia : an international journal of headache2018
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Article in Cephalalgia : an international journal of headache, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.Cephalalgia : an international journal of headache · 2021Pooled it
- Selective vulnerability of GABAergic neurons in chronic migraine.The journal of headache and pain · 2025Article
- Enhancement of the endocannabinoid system through monoacylglycerol lipase inhibition relieves migraine-associated pain in mice.The journal of headache and pain · 2025Article
- Understanding Headaches Attributed to Cranial and/or Cervical Vascular Disorders: Insights and Challenges for Neurologists.Pain and therapy · 2024Review
- Oxidative Stress and Migraine.Molecular neurobiology · 2024Review
- Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine.Headache · 2024Article
- Molecular nociceptive mechanisms in migraine: The migraine cascade.European journal of neurology · 2024Review
- Migraine: Advances in the Pathogenesis and Treatment.Neurology international · 2023Review
- Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023Review
- Peroxynitrite Contributes to Behavioral Responses, Increased Trigeminal Excitability, and Changes in Mitochondrial Function in a Preclinical Model of Migraine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.The journal of headache and pain · 2022Article
- Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation.The journal of headache and pain · 2021Article
- A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.Headache · 2021Article
- Optogenetic Spreading Depression Elicits Trigeminal Pain and Anxiety Behavior.Annals of neurology · 2021Article
- α6GABANeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Nitric oxide signalling in the brain and its control of bodily functions.British journal of pharmacology · 2020Review
- Forebrain delta opioid receptors regulate the response of delta agonist in models of migraine and opioid-induced hyperalgesia.Scientific reports · 2020Article
- NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.Neuropharmacology · 2020Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Background Nitric oxide (NO) has been heavily implicated in migraine. Nitroglycerin is a prototypic NO-donor, and triggers migraine in humans. However, nitroglycerin also induces oxidative/nitrosative stress and is a source of peroxynitrite - factors previously linked with migraine etiology. Soluble guanylyl cyclase (sGC) is the high affinity NO receptor in the body, and the aim of this study was to identify the precise role of sGC in acute and chronic migraine. Methods We developed a novel brain-bioavailable sGC stimulator (VL-102), and tested its hyperalgesic properties in mice. We also determined the effect of VL-102 on c-fos and calcitonin gene related peptide (CGRP) immunoreactivity within the trigeminovascular complex. In addition, we also tested the known sGC inhibitor, ODQ, within the chronic nitroglycerin migraine model. Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate. In addition, VL-102 also increased c-fos and CGRP expressing cells within the trigeminovascular complex. Importantly, ODQ completely inhibited acute and chronic hyperalgesia induced by nitroglycerin. ODQ also blocked hyperalgesia already established by chronic nitroglycerin, implicating this pathway in migraine chronicity. Conclusions These results indicate that nitroglycerin causes migraine-related pain through stimulation of the sGC pathway, and that super-activation of this receptor may be an important component for the maintenance of chronic migraine. This work opens the possibility for negative sGC modulators as novel migraine therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.